Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Shares of Novavax have come under renewed scrutiny as analysts update their fair value estimates in light of recent strategic shifts. The consensus analyst price target for Novavax stock has edged ...

Novavax expects 2026 adjusted revenue between $185 million and $205 million, excluding royalties and sales from its licensing ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may translate into big problems for Johnson & Johnson, Merck, and other ...

(Reuters) -Novavax beat Wall Street expectations for third-quarter revenue on Thursday, helped by milestone payments tied to ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

In addition to TD Cowen, Novavax also received a Hold from TR | OpenAI – 4o’s Dex Genotek in a report issued on October 25. However, on October 24, Cantor Fitzgerald initiated coverage with a Buy ...